Skip to main content

Advertisement

SpringerLink
Log in

Cognitive Impairment and Depression in Mastocytosis: A Synthesis of the Literature

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Symptoms of depression and cognitive dysfunction are commonly reported in mastocytosis. The aims of this review paper are to summarize the current literature on cognitive dysfunction and depressive symptoms, elucidate some of the mechanistic pathways underlying depressive symptoms in mastocytosis, identify gaps in the literature, and offer guidance for future research in this area.

Recent Findings

The study of cognition and depression in mastocytosis is in its infancy and the methodological flaws of the current literature limit interpretability. There is preliminary evidence that some individuals with mastocytosis might experience mild deficits in memory. On average, depression symptom scores fell within the mild to moderate or sub-syndromal range. Regrettably, only one study utilized a standardized diagnostic instrument to assess major depressive disorder. The authors’ tendency to inaccurately equate depressive symptoms with a diagnosis of major depressive disorder presents a notable issue.

Summary

The prevalence of cognitive deficits and depression appears to be similar to other chronic illnesses. Future work needs to better characterize cognition and characterize “depression” in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

No datasets were generated or analyzed during the current study.

References

  1. Stewart KE, Ross D, Hartley S. Patient adaptation to chronic illness. In: Handbook of clinical health psychology, vol. 2. Washington: Disorders of behavior and health. American Psychological Association; 2004. p. 405–21.

    Google Scholar 

  2. Dehnavi SR, Heidarian F, Ashtari F, Shaygannejad V. Psychological well-being in people with multiple sclerosis in an Iranian population. J Res Med Sci. 2015;20. https://doi.org/10.4103/1735-1995.165942.

  3. Rigby SA, Domenech C, Thornton EW, Tedman S, Young CA. Development and validation of a self-efficacy measure for people with multiple sclerosis: the Multiple Sclerosis Self-efficacy Scale. Multiple Sclerosis. 2003;9. https://doi.org/10.1191/1352458503ms870oa.

  4. Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, Valent P, Akin C. The mastocytosis society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Prac 2. 2014. https://doi.org/10.1016/j.jaip.2013.09.004.

  5. Krause K, Zuberbier T, Maurer M. Modern approaches to the diagnosis and treatment of cold contact urticaria. Curr Allergy Asthma Rep. 2010;10.

  6. Silva I, Carvalho S, Pinto PL, Machado S, Rosado Pinto J. Mastocytosis: a rare case of anaphylaxis in paediatric age and literature review. Allergol Immunopathol (Madr) 2008;36.

  7. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, Castells M, Escribano L, Hartmann K, Lieberman P, Nedoszytko B, Orfao A, Schwartz LB, Sotlar K, Sperr WR, Triggiani M, Valenta R, Horny HP, Metcalfe DD. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157. https://doi.org/10.1159/000328760.

  8. Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS One. 2011;6.

  9. Jennings SV, Slee VM, Zack RM, et al. Patient perceptions in mast cell disorders. Immunol Allergy Clin North Am. 2018;38(3). https://doi.org/10.1016/j.iac.2018.04.006.

  10. Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palmérini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barete S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A. Case-control cohort study of patient’s perceptions of disability in mastocytosis. PLoS One. 2008;3. https://doi.org/10.1371/journal.pone.0002266.

  11. Nicoloro-Santabarbara J, Lobel M, Wolfe D. Psychosocial impact of mast cell disorders: pilot investigation of a rare and understudied disease. J Health Psychol. 2017;22. https://doi.org/10.1177/1359105315626784.

  12. Vermeiren MR, Kranenburg LW, van Daele PLA, Gerth van Wijk R, Hermans MAW Psychological functioning and quality of life in patients with mastocytosis: a cross-sectional study. Ann Allergy Asthma Immunol. 2020;124. https://doi.org/10.1016/j.anai.2019.12.020.

  13. Jensen B, Broesby-Olsen S, Bindslev-Jensen C, Nielsen DS. Everyday life and mastocytosis from a patient perspective—a qualitative study. J Clin Nurs. 2019;28(7–8). https://doi.org/10.1111/jocn.14676.

  14. Pulfer S, Ziehfreund S, Gebhard J, et al. Health-related quality of life and influencing factors in adults with nonadvanced mastocytosis—a cross-sectional study and qualitative approach. J Allerg Clin Immunol In Pract. 2021;9(8). https://doi.org/10.1016/j.jaip.2021.04.059.

  15. Siebenhaar F, Von Tschirnhaus E, Hartmann K, et al. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy Eur J Allerg Clin Immunol. 2016;71(6). https://doi.org/10.1111/all.12842.

  16. EURORDIS Rare Disease Europe. International joint recommendations to address specific needs of undiagnosed rare disease patients. 2016.

  17. Kliegman RM, Bordini BJ, Basel D, Nocton JJ. How doctors think: common diagnostic errors in clinical judgment—lessons from an undiagnosed and rare disease program. Pediatr Clin North Am. 2017;64.

  18. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. The Lancet. 2008;371.

  19. Affleck G, Tennen H, Pfeiffer C, Fifield J. Appraisals of control and predictability in adapting to a chronic disease. J Pers Soc Psychol. 1987;53. https://doi.org/10.1037/0022-3514.53.2.273.

  20. Cohen S. Aftereffects of stress on human performance and social behavior: a review of research and theory. Psychol Bull. 1980;88. https://doi.org/10.1037/0033-2909.88.1.82.

  21. Felton BJ, Revenson TA. Coping with chronic illness: a study of illness controllability and the influence of coping strategies on psychological adjustment. J Consult Clin Psychol. 1984;52. https://doi.org/10.1037/0022-006X.52.3.343.

  22. Moos RH, Tsu VD. The crisis of physical illness: an overview. In: Coping with Physical Illness. 1977.

  23. Huyard C. What, if anything, is specific about having a rare disorder? Patients’ judgements on being ill and being rare. Health Expectations. 2009;12. https://doi.org/10.1111/j.1369-7625.2009.00552.x.

  24. (2011) Rare diseases and orphan products. National Academies Press, Washington, D.C.

  25. Chester JG, Grande LJ, Milberg WP, McGlinchey RE, Lipsitz LA, Rudolph JL. Cognitive screening in community-dwelling elders: performance on the clock-in-the-box. Am J Med. 2011;124. https://doi.org/10.1016/j.amjmed.2011.02.023.

  26. Soter NA, Wasserman SI, Austen KF. A double blind crossover trial of oral disodium cromoglycate (DSCG) in human mastocytosis. Clin Res. 1978;26.

  27. Jendoubi F, Severino-Freire M, Negretto M, Arbus C, Paul C, Bulai Livideanu C. Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients. Orphanet J Rare Dis. 2021;16. https://doi.org/10.1186/s13023-021-01747-y.

  28. Moura DS, Sultan S, Georgin-Lavialle S, Barete S, Lortholary O, Gaillard R, Hermine O. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PLoS One. 2012;7. https://doi.org/10.1371/journal.pone.0039468.

  29. Chlebowski C. Wechsler Memory Scale all versions. In: Encyclopedia of Clinical Neuropsychology. 2011.

  30. Wambach D, Lamar M, Swenson R, Penney DL, Kaplan E, Libon DJ. Digit Span. In: Encyclopedia of clinical neuropsychology. New York, New York, NY: Springer; 2011. p. 844–9.

    Chapter  Google Scholar 

  31. Rosvold HE, Mirsky AF, Sarason I, Bransome ED, Beck LH. A continuous performance test of brain damage. J Consult Psychol. 1956;20. https://doi.org/10.1037/h0043220.

  32. Folstein M, Folstein S, McHugh P. Mini-mental state examination (MMS, MMSE). APA PsycTests. 1975.

  33. Spolak-Bobryk N, Romantowski J, Kujawska-Danecka H, Niedoszytko M. Mastocytosis patients’ cognitive dysfunctions correlate with the presence of spindle-shaped mast cells in bone marrow. Clin Transl Allergy. 2022;12.

  34. Rogers MP, Bloomingdale K, Murawski BJ, Soter NA, Reich P, Austen KF. Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med. 1986;48. https://doi.org/10.1097/00006842-198607000-00006.

  35. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nuñez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25.

  36. Beck AT, Steer RA, Brown G. Beck depression inventory–II (BDI-II). Psychological assessment (APA PsycTests). 1996;10.

  37. Radloff LS. The CES-D Scale: a Self-Report Depression Scale for research in the general population. Appl Psychol Meas. 1977;1. https://doi.org/10.1177/014662167700100306.

  38. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–70. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x.

    Article  CAS  PubMed  Google Scholar 

  39. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale--preliminary report. Psychopharmacol Bull. 1973;9.

  40. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23. https://doi.org/10.1136/jnnp.23.1.56.

  41. Georgin-Lavialle S, Moura DS, Bruneau J, Chauvet-Gélinier JC, Damaj G, Soucie E, Barete S, Gacon AL, Grandpeix-Guyodo C, Suarez F, Launay JM, Durieu I, Esparcieux A, Guichard I, Sparsa A, Nicolini F, Gennes C de, Trojak B, Haffen E, Vandel P, Lortholary O, Dubreuil P, Bonin B, Sultan S, Teyssier JR, Hermine O. Leukocyte telomere length in mastocytosis: correlations with depression and perceived stress. Brain Behav Immun. 2014;35. https://doi.org/10.1016/j.bbi.2013.07.009.

  42. Georgin-Lavialle S, Moura DS, Salvador A, Chauvet-Gelinier JC, Launay JM, Damaj G, Côté F, Soucié E, Chandesris MO, Barète S, Grandpeix-Guyodo C, Bachmeyer C, Alyanakian MA, Aouba A, Lortholary O, Dubreuil P, Teyssier JR, Trojak B, Haffen E, Vandel P, Bonin B, Hermine O, Gaillard R. Mast cells’ involvement in inflammation pathways linked to depression: evidence in mastocytosis. Mol Psychiatry. 2016;21. https://doi.org/10.1038/mp.2015.216.

  43. Lortholary O, Chandesris MO, Livideanu CB, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Lavialle SG, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. The Lancet 2017;389. https://doi.org/10.1016/S0140-6736(16)31403-9.

  44. Spolak-Bobryk N, Niedoszytko M, Jassem E, Chełmińska M, Lange M, Majkowicz M, Nedoszytko B, Borchet J. The role of the clinical and psychological symptoms of mastocytosis in the patient’s quality of life. Postepy Dermatol Alergol. 2022;39. https://doi.org/10.5114/ada.2021.108433

  45. Boddaert N, Salvador A, Chandesris MO, Lemaître H, Grévent D, Gauthier C, Naggara O, Georgin-Lavialle S, Moura DS, Munsch F, Jaafari N, Zilbovicius M, Lortholary O, Gaillard R, Hermine O. Neuroimaging evidence of brain abnormalities in mastocytosis. Transl Psychiatry 2017;7. https://doi.org/10.1038/TP.2017.137.

  46. McNair D, Lord M, Droppleman L. Profile of mood states. Educational and Industrial Testing Service., San Diego. 1981.

  47. American Psychiatric Association. Patient-reported outcome measures (PROMs) descriptions. https://www.psychiatry.org/File%20Library/Psychiatrists/Registry/PsychPRO-PROMs-Description-Guide.pdf.

  48. Ettema J, Arrindell W. SCL-90: manual for a multidimensional indicator of psycho-pathology. 2003.

  49. Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmérini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010;85. https://doi.org/10.1002/ajh.21894.

  50. Arock M, Akin C, Hermine O, Valent P. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. Eur J Haematol. 2015;94.

  51. Valent P, Horny H, Li C. Mastocytosis. In: Jaffe E, Harris N, Stein H, Vardiman JW, editors. World Health Organization (WHO) classification of tumours. Lyon, France: IARC Press; 2001. p. 291–302.

    Google Scholar 

  52. Barbieri MA, Sorbara EE, Russo G, Cicala G, Franchina T, Santarpia M, Silvestris N, Spina E. Neuropsychiatric adverse drug reactions with tyrosine kinase inhibitors in gastrointestinal stromal tumors: an analysis from the European Spontaneous adverse event reporting system. Cancers (Basel). 2023;15. https://doi.org/10.3390/cancers15061851.

  53. DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27. https://doi.org/10.1038/s41591-021-01538-9.

  54. George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Avapritinib in patients with advanced gastrointestinal stromal tumors following at least three prior lines of therapy. Oncologist. 2021;26. https://doi.org/10.1002/onco.13674.

  55. Joseph CP, Abaricia SN, Angelis MA, Polson K, Jones RL, Kang YK, Riedel RF, Schöffski P, Serrano C, Trent J, Tetzlaff ED, Si TD, Zhou T, Doyle A, Bauer S, Roche M, Havnaer T. Optimal avapritinib treatment strategies for patients with metastatic or unresectable gastrointestinal stromal tumors. Oncologist. 2021;26. https://doi.org/10.1002/onco.13632.

  56. Horny HP, Sotlar K, Valent P, Hartmann K. Mastocytosis - a disease of the hematopoietic stem cell. Dtsch Arztebl. 2008;105.

  57. Georgin-Lavialle S, Lhermitte L, Baude C, Barete S, Bruneau J, Launay JM, Chandesris MO, Hanssens K, De Gennes C, Damaj G, Lanternier F, Hamidou M, Lortholary O, Dubreuil P, Feger F, Lepelletier Y, Hermine O. Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor. Blood. 2011;118. https://doi.org/10.1182/blood-2011-02-335950.

  58. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the Fatigue Impact Scale. Clin Infect Dis. 1994;18. https://doi.org/10.1093/clinids/18.Supplement_1.S79.

  59. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9.

  60. Irwin M. Psychoneuroimmunology of depression: clinical implications. In: Brain, Behavior, and Immunity. 2002.

  61. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007;21.

  62. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35.

  63. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16.

  64. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull 2014;140. https://doi.org/10.1037/a0035302.

  65. Cho JHJ, Irwin MR, Eisenberger NI, Lamkin DM, Cole SW. Transcriptomic predictors of inflammation-induced depressed mood. Neuropsychopharmacology. 2019;44. https://doi.org/10.1038/s41386-019-0316-9.

  66. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, Vogt GJ, Massung B, Miller AH. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2009;65. https://doi.org/10.1016/j.biopsych.2008.08.010.

  67. Hermans MAW, Heeringa JJ, Swagemakers SGA, Schrijver B, van Daele PLA, van der Spek PJ, van Hagen PM, van Zelm MC, Dik WA. Altered leukocyte subsets and immune proteome indicate proinflammatory mechanisms in mastocytosis. J Allergy Clin Immunol. 2022;150. https://doi.org/10.1016/j.jaci.2021.12.786.

  68. Pérez‐Pons A, Jara‐Acevedo M, Henriques A, Navarro‐Navarro P, García‐Montero AC, Álvarez‐Twose I, Pedreira CE, Sánchez‐Muñoz L, Damasceno D, Caldas C, Muñoz‐González JI, Matito A, Flores‐Montero J, González‐López O, Criado I, Mayado A, Orfao A. Altered innate immune profile in blood of systemic mastocytosis patients. Clin Transl Allergy 2022;12. https://doi.org/10.1002/clt2.12167.

  69. Tobío A, Bandara G, Morris DA, Kim DK, O’Connell MP, Komarow HD, Carter MC, Smrz D, Metcalfe DD, Olivera A. Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. Haematologica. 2020;105. https://doi.org/10.3324/haematol.2018.212126.

  70. Rabenhorst A, Christopeit B, Leja S, Gerbaulet A, Kleiner S, Förster A, Raap U, Wickenhauser C, Hartmann K. Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol. 2013;132. https://doi.org/10.1016/j.jaci.2013.06.019.

  71. Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol. 2005;115. https://doi.org/10.1016/j.clim.2005.01.011.

  72. Mayado A, Teodosio C, Garcia-Montero AC, Matito A, Rodriguez-Caballero A, Morgado JM, Muñiz C, Jara-Acevedo M, Álvarez-Twose I, Sanchez-Munõz L, Matarraz S, Caldas C, Munoz-Gonzalez JI, Escribano L, Orfao A. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia. 2016;30. https://doi.org/10.1038/leu.2015.176.

  73. Barberio B, Zamani M, Black CJ, Savarino E V., Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6. https://doi.org/10.1016/S2468-1253(21)00014-5.

  74. Hopkins CWP, Powell N, Norton C, Dumbrill JL, Hayee BH, Moulton CD. Cognitive impairment in adult inflammatory bowel disease: a systematic review and meta-analysis. J Acad Consult Liaison Psychiatry. 2021;62. https://doi.org/10.1016/j.psym.2020.10.002.

  75. Barsky A, Silbersweig D. Depression in medical illness, 1st ed. McGraw Hill Professional. 2017.

  76. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7:1139–51. https://doi.org/10.1016/S1474-4422(08)70259-X.

    Article  PubMed  Google Scholar 

  77. Lok EYC, Mok CC, Cheng CW, Cheung EFC. Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis. Psychosomatics 2010;51. https://doi.org/10.1176/appi.psy.51.4.338.

  78. Meade T, Manolios N, Cumming SR, Conaghan PG, Katz P. Cognitive impairment in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2018;70. https://doi.org/10.1002/acr.23243.

  79. Uguz F, Akman C, Kucuksarac S, Tufekci O. Anti-tumor necrosis factor-α therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci 2009;63. https://doi.org/10.1111/j.1440-1819.2008.01905.x.

  80. Rayes H Al, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, Mustafa A, Su J, Lambiris P, Mosca M, Touma Z. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48.

  81. Zhang L, Fu T, Yin R, Zhang Q, Shen B. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry. 2017;17. https://doi.org/10.1186/s12888-017-1234-1.

  82. Irani F, Barbone JM, Beausoleil J, Gerald L. Is asthma associated with cognitive impairments? A meta-analytic review. J Clin Exp Neuropsychol 2017;39. https://doi.org/10.1080/13803395.2017.1288802.

  83. Zielinski TA, Brown S, Nejtek VA, Kahn DA, Moore JJ, Rush AJ. Depression in asthma: prevalence and clinical implications. The Primary Care Companion to The Journal of Clinical Psychiatry. 2000;02:153–8. https://doi.org/10.4088/PCC.v02n0501.

    Article  Google Scholar 

  84. DiGiuseppe G, Blair M, Morrow SA. Short report: prevalence of cognitive impairment in newly diagnosed relapsing-remitting multiple sclerosis. Int J MS Care. 2018;20:153–7. https://doi.org/10.7224/1537-2073.2017-029.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Ferreira MLB. Cognitive deficits in multiple sclerosis: a systematic review. Arq Neuropsiquiatr. 2010;68.

  86. Goverover Y, Strober L, Chiaravalloti N, DeLuca J. Factors that moderate activity limitation and participation restriction in people with multiple sclerosis. Am J Occup Ther. 2015;69. https://doi.org/10.5014/ajot.2015.014332.

  87. Gwinnutt JM, Toyoda T, Barraclough M, Verstappen SMM, Hornberger M, MacGregor A. Cognitive impairment in the immune-mediated inflammatory diseases compared with age-matched controls: systematic review and meta-regression. Semin Arthritis Rheum. 2023;58. https://doi.org/10.1016/j.semarthrit.2022.152131.

  88. Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF. Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Mult Scler. 2008;14. https://doi.org/10.1177/1352458508095004.

  89. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41. https://doi.org/10.1212/WNL.41.5.685.

  90. Rouleau I, Dagenais E, Tremblay A, Demers M, Roger É, Jobin C, Duquette P. Prospective memory impairment in multiple sclerosis: a review. Clin Neuropsychol. 2018;32. https://doi.org/10.1080/13854046.2017.1361473.

  91. Costa SL, Genova HM, Deluca J, Chiaravalloti ND. Information processing speed in multiple sclerosis: past, present, and future. Mult Scler. 2017;23.

  92. Drew M, Tippett LJ, Starkey NJ, Isler RB. Executive dysfunction and cognitive impairment in a large community-based sample with multiple sclerosis from New Zealand: a descriptive study. Arch Clin Neuropsychol. 2008;23. https://doi.org/10.1016/j.acn.2007.09.005.

  93. Dubruille S, Libert Y, Roos M, Vandenbossche S, Collard A, Meuleman N, Maerevoet M, Etienne AM, Reynaert C, Razavi D, Bron D. Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: major impact of cognition. J Geriatr Oncol 2015;6. https://doi.org/10.1016/j.jgo.2015.07.006.

  94. Hshieh TT, Jung WF, Grande LJ, Chen J, Stone RM, Soiffer RJ, Driver JA, Abel GA. Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers. JAMA Oncol. 2018;4. https://doi.org/10.1001/jamaoncol.2017.5674.

  95. Mayer SA, Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Connolly ES. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology. 2002;59. https://doi.org/10.1212/01.WNL.0000035748.91128.C2.

  96. Morris C, Mitchell JW, Moorey H, Younan HC, Tadros G, Turner AM. Memory, attention and fluency deficits in COPD may be a specific form of cognitive impairment. ERJ Open Res. 2019;5. https://doi.org/10.1183/23120541.00229-2018.

  97. Konstantinou GN, Konstantinou GN. Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis. Clin Transl Allergy. 2019;9.

  98. Hale ED, Treharne GJ, Kitas GD. The common-sense model of self-regulation of health and illness: how can we use it to understand and respond to our patients’ needs? Rheumatology. 2007;46.

  99. Hill S, Dziedzic K, Thomas E, Baker SR, Croft P. The illness perceptions associated with health and behavioural outcomes in people with musculoskeletal hand problems: findings from the North Staffordshire Osteoarthritis Project (NorStOP). Rheumatology. 2007;46. https://doi.org/10.1093/rheumatology/kem015.

  100. Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005;32.

  101. Binzer S, McKay KA, Brenner P, Hillert J, Manouchehrinia A. Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study. Neurology. 2019;93. https://doi.org/10.1212/WNL.0000000000008617.

  102. Bosley CM, Fosbury JA, Cochrane GM. The psychological factors associated with poor compliance with treatment in asthma. Eur Respir J. 1995;8. https://doi.org/10.1183/09031936.95.08060899.

  103. Cai Q, Teeple A, Wu B, Muser E. Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis. J Med Econ. 2019;22. https://doi.org/10.1080/13696998.2019.1638788.

  104. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med. 2000;160. https://doi.org/10.1001/archinte.160.14.2101.

  105. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134. https://doi.org/10.1038/jid.2013.508.

  106. Engin B, Uguz F, Yilmaz E, Özdemir M, Mevlitoglu I. The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria. J Eur Acad Dermat Venereol. 2008;22. https://doi.org/10.1111/j.1468-3083.2007.02324.x.

  107. Guelfucci F, Kaneko Y, Mahlich J, Sruamsiri R. Cost of depression in Japanese patients with rheumatoid arthritis: evidence from administrative data. Rheumatol Ther. 2018;5. https://doi.org/10.1007/s40744-018-0096-4.

  108. Joyce AT, Smith P, Khandker R, Melin JM, Singh A. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol. 2009;36. https://doi.org/10.3899/jrheum.080670.

  109. Li N, Chan E, Peterson S. The economic burden of depression among adults with rheumatoid arthritis in the United States. J Med Econ. 2019;22. https://doi.org/10.1080/13696998.2019.1572015.

  110. Löwe B, Willand L, Eich W, Zipfel S, Ho AD, Herzog W, Fiehn C. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. Psychosom Med 2004;66. https://doi.org/10.1097/01.psy.0000126203.89941.a3.

  111. Marrie RA, Walld R, Bolton JM, Sareen J, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN. Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. Gen Hosp Psychiatry. 2018;53. https://doi.org/10.1016/j.genhosppsych.2018.06.001.

  112. Palladino R, Chataway J, Majeed A, Marrie RA. Interface of multiple sclerosis, depression, vascular disease, and mortality: a population-based matched cohort study. Neurology. 2021;97. https://doi.org/10.1212/WNL.0000000000012610.

  113. Scherrer JF, Virgo KS, Zeringue A, Bucholz KK, Jacob T, Johnson RG, True WR, Carney RM, Freedland KE, Xian H, Caplan L, McDonald J, Eisen SA. Depression increases risk of incident myocardial infarction among Veterans Administration patients with rheumatoid arthritis. Gen Hosp Psychiatry. 2009;31. https://doi.org/10.1016/j.genhosppsych.2009.04.001.

  114. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005;76.

  115. Washington F, Langdon D. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol. 2022;269.

  116. Golan D, Gross B, Miller A, Klil-Drori S, Lavi I, Shiller M, Honigman S, Almog R, Segol O. Cognitive function of patients with Crohn’s disease is associated with intestinal disease activity. Inflamm Bowel Dis. 2016;22. https://doi.org/10.1097/MIB.0000000000000594.

  117. Miskowiak KW, Petersen JZ, Ott CV, Knorr U, Kessing LV, Gallagher P, Robinson L. Predictors of the discrepancy between objective and subjective cognition in bipolar disorder: a novel methodology. Acta Psychiatr Scand. 2016;134. https://doi.org/10.1111/acps.12649.

  118. First MB, Williams JBW, Karg RS, Spitzer RL. Structured clinical interview for DSM-5—research version (SCID-5 for DSM-5, research version; SCID-5-RV). American Psychiatric Association, Arlington, VA. 2015.

  119. Stenn PG. Depression in the medically ill. The Canadian Journal of Psychiatry. 1996;41:65–6. https://doi.org/10.1177/070674379604100201.

    Article  CAS  PubMed  Google Scholar 

  120. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343. https://doi.org/10.1056/nejm200012283432607.

  121. Wright J, Basco M, These M. Learning cognitive-behavior therapy: an illustrated guide. American Psychiatric Publishing, Inc. 2006.

  122. Cukor D. Use of CBT to treat depression among patients on hemodialysis. Psychiatr Serv. 2007;58. https://doi.org/10.1176/ps.2007.58.5.711.

  123. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, Bienfait KL, Friedman J. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168. https://doi.org/10.1176/appi.ajp.2011.10111669.

  124. Hind D, Cotter J, Thake A, Bradburn M, Cooper C, Isaac C, House A. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry. 2014;14. https://doi.org/10.1186/1471-244X-14-5.

  125. Qureshi AA, Awosika O, Baruffi F, Rengifo-Pardo M, Ehrlich A. Psychological therapies in management of psoriatic skin disease: a systematic review. Am J Clin Dermatol. 2019;20.

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA, 02115, USA

    Jennifer Nicoloro-SantaBarbara, Marzieh Majd & Katherine E. Burdick

  2. Harvard Medical School, Boston, MA, USA

    Jennifer Nicoloro-SantaBarbara, Marzieh Majd, Katherine E. Burdick & Matthew P. Giannetti

  3. Department of Psychology, Northeastern University, Boston, MA, USA

    Victoria Dixon

  4. Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Boston, MA, USA

    Matthew P. Giannetti

Authors
  1. Jennifer Nicoloro-SantaBarbara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marzieh Majd
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katherine E. Burdick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Victoria Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthew P. Giannetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JNSB, MM, KB, VD, and MM wrote the manuscript text. All authors reviewed the manuscript.

Corresponding author

Correspondence to Jennifer Nicoloro-SantaBarbara.

Ethics declarations

Conflict of Interest

Dr. Burdick reports grants and personal fees from Breakthrough Discoveries for thriving with Bipolar Disorder and personal fees from Merck, outside the submitted work. Jennifer Nicoloro-SantaBarbara reports personal fees from Cogent Biosciences and receives consulting fees from Cogent Biosciences. Marzieh Majd reports no conflict of interest. Victoria Dixon reports no conflict of interest. Matthew Giannetti reports personal and research fees from Blueprint Medicines and consulting fees from Cogent Biosciences and Inmagene.

Human and Animal Rights and Informed Consent

All reported studies/experiments involving human or animal subjects performed by the authors were in accordance with the ethical standards of institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nicoloro-SantaBarbara, J., Majd, M., Burdick, K.E. et al. Cognitive Impairment and Depression in Mastocytosis: A Synthesis of the Literature. Curr Allergy Asthma Rep 24, 53–62 (2024). https://doi.org/10.1007/s11882-024-01127-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-024-01127-z

Keywords

Search

Navigation